keyword
MENU ▼
Read by QxMD icon Read
search

EMA

keyword
https://www.readbyqxmd.com/read/29783804/-acquired-cystic-kidney-disease-associated-renal-cell-carcinoma-a-clinicopathologic-study-of-three-cases
#1
W Zhang, L L Xu, W J Yu, Q Wang, Y X Jiang, Y Liu, Y J Li
Objective: To study the clinicopathologic, immunohistochemical (IHC), histogenetic and prognostic features of acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC). Methods: Three cases of ACKD-RCC, including two from 401 Hospital of PLA and one from the Affiliated Hospital of Qingdao University were studied by clinical, histological and IHC analysis with review of relevant literature. Results: All the three patients were male, ranging from 46 to 78 years old. All patients had history of chronic renal failure; two patients were treated with hemodialysis for 9 years and 11 years, respectively...
May 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29781751/posology-adjustments-of-oral-antineoplastic-agents-for-special-populations-patients-with-renal-impairment-hepatic-impairment-and-hematologic-toxicities
#2
Julieta González, Matías Quiroga, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Ana Herranz-Alonso, María Sanjurjo Sáez
BACKGROUND: Oral antineoplastic agents (OAA) have reached 30-50% of all antineoplastic treatments. Although they seem safer than parenteral therapy, many severe problems can occur if the dose is not adequately adjusted in special situations. Our objective is to create a comprehensive guide with dosage adjustment recommendations for OAA in cases of renal and hepatic impairment and hematologic toxicities. RESEARCH DESIGN AND METHODS: We analyzed all OAA approved by EMA in July 2017...
May 21, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29774424/lingual-and-jaw-kinematic-abnormalities-precede-speech-and-swallowing-impairments-in-als
#3
Bridget J Perry, Rosemary Martino, Yana Yunusova, Emily K Plowman, Jordan R Green
Early identification of bulbar involvement in persons with ALS is critical for improving diagnosis and prognosis; however, efficacious diagnostic markers have not yet been identified. The purpose of this study was to determine whether kinematic changes of the tongue and jaw during swallowing, measured using 3D electromagnetic articulography (EMA), predate clinically identifiable symptoms of speech and swallowing impairment in persons diagnosed with ALS. Data were collected from 16 adults diagnosed with ALS and 18 neurotypical controls...
May 17, 2018: Dysphagia
https://www.readbyqxmd.com/read/29771135/electromembrane-extraction-of-substances-with-weakly-basic-properties-a-fundamental-study-with-benzodiazepines
#4
Linda Vårdal, Elisabeth L Øiestad, Astrid Gjelstad, Stig Pedersen-Bjergaard
AIM: Electromembrane extraction (EME) of weakly basic benzodiazepines was investigated (-1.47 < pKa < 5.01). MATERIALS & METHODS: 96-well EME was performed with strongly acidic conditions in the acceptor solution using 250-mM trifluoroacetic acid to maximize ionization. RESULTS & CONCLUSION: Recoveries more than 80% were obtained for analytes with pKa > 2, whereas EME was less efficient for substances with pKa < 2...
May 17, 2018: Bioanalysis
https://www.readbyqxmd.com/read/29767767/waking-up-on-the-wrong-side-of-the-bed-the-effects-of-stress-anticipation-on-working-memory-in-daily-life
#5
Jinshil Hyun, Martin J Sliwinski, Joshua M Smyth
Objectives: The aim of this study was to examine the association between stress anticipated for the upcoming day and cognitive function later on that day, and how this relationship differed across age. Method: A diverse adult community sample (N = 240, age 25-65 years) completed ecological momentary assessment (EMA) reports for 2 weeks on a smartphone; each day they completed a morning survey upon waking, beeped surveys at five times during a day, and an end-of-day survey...
May 15, 2018: Journals of Gerontology. Series B, Psychological Sciences and Social Sciences
https://www.readbyqxmd.com/read/29762040/orally-bioavailable-and-effective-buparvaquone-lipid-based-nanomedicines-for-visceral-leishmaniasis
#6
Lindsay A Smith, Dolores Remedios Serrano, Marion Mauger, Francisco Bolás-Fernández, Maria Auxiliadora Dea-Ayuela, Aikaterini Lalatsa
Nano-enabled lipid based drug delivery systems offer a platform to overcome challenges encountered with current failed leads in the treatment of parasitic and infectious diseases. When prepared with FDA or EMA approved excipients, they can be readily translated without the need for further toxicological studies, while they remain affordable and amenable to scale-up. Buparvaquone (BPQ), a hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically translate as a viable treatment for visceral leishmaniasis due to its poor oral bioavailability limited by its poor aqueous solubility (BCS Class II drug)...
May 15, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29761688/collagenase-clostridium-histolyticum-a-novel-medical-treatment-for-peyronie-s-disease
#7
Amr Abdel Raheem, Mark Johnson, David Ralph, Giulio Garaffa
INTRODUCTION: Peyronie's disease (PD) affects up to 9% of the male population. PD causes scarring of the tunica albuginea of the penis which leads to penile deformity making sexual intercourse difficult or impossible. PD also causes significant psychological, emotional and relationship difficulties for both patient and partner. Up until the licencing of Collagenase clostridium histolyticum (CCH) (Xiapex®, Xiaflex®), surgical correction of the penile deformity was the mainstay of treatment...
May 14, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/29760435/biomarkers-as-drug-development-tools-discovery-validation-qualification-and-use
#8
REVIEW
Virginia B Kraus
The 21st Century Cures Act, approved in the USA in December 2016, has encouraged the establishment of the national Precision Medicine Initiative and the augmentation of efforts to address disease prevention, diagnosis and treatment on the basis of a molecular understanding of disease. The Act adopts into law the formal process, developed by the FDA, of qualification of drug development tools, including biomarkers and clinical outcome assessments, to increase the efficiency of clinical trials and encourage an era of molecular medicine...
May 14, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29759960/temporal-associations-between-social-activity-and-mood-fatigue-and-pain-in-older-adults-with-hiv-an-ecological-momentary-assessment-study
#9
Emily W Paolillo, Bin Tang, Colin A Depp, Alexandra S Rooney, Florin Vaida, Christopher N Kaufmann, Brent T Mausbach, David J Moore, Raeanne C Moore
BACKGROUND: Social isolation is associated with an increased risk for mental and physical health problems, especially among older persons living with HIV (PLWH). Thus, there is a need to better understand real-time temporal associations between social activity and mood- and health-related factors in this population to inform possible future interventions. OBJECTIVE: This study aims to examine real-time relationships between social activity and mood, fatigue, and pain in a sample of older PLWH...
May 14, 2018: JMIR Mental Health
https://www.readbyqxmd.com/read/29757709/how-to-assess-the-best-immunohistochemical-panel-in-the-diagnosis-of-malignant-pleural-mesothelioma-in-a-pathology-lab
#10
Mona Mlika, Oumeima Lamzibri, Saoussen Bacha, Soumeya Laabidi, Chokri Haddouchi, Faouzi El Mezni
BACKGROUND: malignant pleural mesothelioma (MPM) is a rare tumor with a challenging diagnosis. Even if, clinical data are mandatory to suspect the diagnosis, the positive diagnosis is based on microscopic features. Morphologic features are still the port of call of the diagnosis but their non specific character and the multiplicity of differential diagnoses made the immunohistochemical markers mandatory for the diagnosis. Many antibodies with a positive diagnostic value including claretinin, mesothelin, WT1 and antibodies with a negative diagnostic value including TTF1, EMA, CD15 are recommended by the scientific societies...
May 14, 2018: Journal of Immunoassay & Immunochemistry
https://www.readbyqxmd.com/read/29756322/european-medicines-agency-approval-of-new-glucose-lowering-medicines-for-type-2-diabetes
#11
Clifford J Bailey
Since 2005 all new glucose-lowering medicines to be used in Europe have required approval by the European Medicines Agency (EMA) through a centralised procedure [1]. This involves assessment of a detailed file of data generated during the preclinical studies and phase 1-3 clinical trials, along with the proposed product label. The file is subject to internal review and some aspects may also receive external review, giving rise to questions that are referred back to the sponsor and may lead to additional studies...
May 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29752142/genetic-diversity-of-theileria-equi-and-babesia-caballi-infecting-horses-of-central-southern-italy-and-preliminary-results-of-its-correlation-with-clinical-and-serological-status
#12
Giuseppe Manna, Antonella Cersini, Roberto Nardini, Leticia Elisa Bartolomé Del Pino, Valeria Antognetti, Maurizio Zini, Raffaella Conti, Raniero Lorenzetti, Vincenzo Veneziano, Gian Luca Autorino, Maria Teresa Scicluna
Babesia caballi and Theileria equi are tick-borne pathogens causing equine piroplasmosis infecting the Equidae family in which they cause significant sanitary and economic losses. Furthermore, equine piroplasmosis is included in the World Animal Health Organization (OIE) notifiable diseases list with possible movement restrictions for positive horses. Thirty-nine EDTA and whole-blood samples collected during 2013 and 2014 from symptomatic and asymptomatic horses of Central-Southern Italy were included in the present study either because of their strongly positive results in Real Time (RT) PCRs targeting the 18S rRNA gene specific for each piroplasm and/or due to their serological ELISA/18S rRNA RT-PCR discordant results...
May 4, 2018: Ticks and Tick-borne Diseases
https://www.readbyqxmd.com/read/29751962/corrigendum-to-jp8-exposure-and-neurocognitive-performance-among-us-air-force-personnel-neurotoxicology-62-2017-170-180
#13
Kristin J Heaton, Alexis L Maule, Kristen W Smith, Ema G Rodrigues, Michael D McClean, Susan P Proctor
No abstract text is available yet for this article.
May 8, 2018: Neurotoxicology
https://www.readbyqxmd.com/read/29749086/imposed-registries-within-the-european-postmarketing-surveillance-system-extended-analysis-and-lessons-learned-for-regulators
#14
Alexandra Pacurariu, Kelly Plueschke, Carla Alonso Olmo, Xavier Kurz
PURPOSE: Building on previous research, we examined whether delayed study start and low patient accrual rates found in 31 postauthorization registry-based studies requested by European Medicines Agency (EMA) are maintained after 2 additional years of follow-up. METHOD: The registries identified in the previous EMA study and the same methodology were used. The follow-up was extended from June 2015 to November 2017. The information available for the following variables was updated: marketing authorization status, study and registry status, study end date, planned duration, number of patients planned to be enrolled, and actual patients enrolled...
May 11, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29747541/risk-benefit-of-dexrazoxane-for-preventing-anthracycline-related-cardiotoxicity-re-evaluating-the-european-labeling
#15
Peter Reichardt, Marie-Dominique Tabone, Jaume Mora, Bruce Morland, Robin L Jones
Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children had not then been established. We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy...
May 11, 2018: Future Oncology
https://www.readbyqxmd.com/read/29747250/-rare-primary-proximal-epithelioid-sarcoma-in-skull-base-clinical-analysis-of-four-cases
#16
Z J Duan, K Yao, Y M Qu, M Ren, Y L Zhang, X L Qi
Objective: To report the clinical and pathological features of primary proximal epithelioid sarcoma (PES) in skull base. Methods: The clinical and pathological features of four cases of PES in skull base from Sanbo Brain Institute of Capital Medical University and Kunming Sanbo Brain Institute were analysed retrospectively. Results: Three cases was female, and one male, the age ranged from 46 to 52 years.All cases occurred in skull base, and sellar region was the main site of involvement.Under the microscope, the tumor cells characterized by epithelioid cell changes, with or without rhabdoid tumor cells...
April 7, 2018: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/29747241/stiripentol-add-on-therapy-for-focal-refractory-epilepsy
#17
REVIEW
Francesco Brigo, Stanley C Igwe, Nicola Luigi Bragazzi
BACKGROUND: This is an updated version of the Cochrane review last published in 2015 (Issue 10). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam, with promising effects. OBJECTIVES: To evaluate the efficacy and tolerability of stiripentol as add-on treatment for people with focal refractory epilepsy who are taking AEDs...
May 10, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29747155/manual-punch-versus-automated-flow-through-sample-desorption-for-dried-blood-spot-lc-ms-ms-analysis-of-voriconazole
#18
Lisa C Martial, Erik van den Hombergh, Cornelis Tump, Otto Halmingh, David M Burger, Erik M van Maarseveen, Roger J Brüggemann, Rob E Aarnoutse
Dried blood spot (DBS) sampling is a patient-friendly alternative for plasma sampling for the purpose of therapeutic drug monitoring (TDM). To speed up the analysis time, an automated flow-through desorption method of DBS samples may be beneficial. This article describes the cross-validation of a manual punch DBS method with an automated desorption (DBS autosampler, DBSA) method for the DBS analysis of the antifungal drug voriconazole, followed by cross-validation of both DBS methods with a plasma-based method, and an assessment of agreement between DBS/DBSA and regular plasma concentration measurements (gold standard) in samples from patients on voriconazole treatment...
April 27, 2018: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29747061/serrated-epithelial-colorectal-polyps-hyperplastic-polyps-sessile-serrated-adenomas-with-perineurial-stroma-clinicopathological-and-molecular-analysis-of-a-new-series
#19
Katharina Erlenbach-Wünsch, Michel Bihl, Arndt Hartmann, Gabriel M Groisman, Michael Vieth, Abbas Agaimy
Serrated colorectal fibroblastic polyps (FPs) are rare benign mucosal lesions composed of serrated epithelial crypts separated and distorted by intimately associated bland spindle cell proliferations with perineurial-like phenotype. We herein describe 21 new FPs affecting 10 females and 9 males aged 45 to 80 yrs. (mean, 62 yrs). Lesions originated in the sigmoid colon/rectosigmoid junction (n = 16), rectum (n = 2), and other parts of the colon (n = 3). Most patients had additional synchronous or metachronous polyps: classical adenomas (12 patients), sessile serrated adenoma/SSA (1 patient), hyperplastic polyps/HPs (7 patients), both HPs and adenomas (6 patients) and colorectal cancer (2 patients)...
May 4, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29746395/a-liquid-chromatography-mass-spectrometry-assay-for-determination-of-perampanel-and-concomitant-antiepileptic-drugs-in-the-plasma-of-patients-with-epilepsy-compared-with-a-fluorescent-hplc-assay
#20
Ugo de Grazia, Annachiara D'Urso, Federica Ranzato, Valentina De Riva, Giorgia Contarato, Giuseppe Billo, Francesco Perini, Elisabetta Galloni
BACKGROUND: Perampanel is a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor, approved as an adjunctive agent for the treatment of partial-onset seizure with or without secondary generalization and for primary generalized tonic-clonic seizure in patients with epilepsy who are at least 12 years of age. Limited information is available about the clinical utility of therapeutic drug monitoring of perampanel and therapeutic ranges are so far not established...
May 9, 2018: Therapeutic Drug Monitoring
keyword
keyword
56538
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"